Zeinali Fatemeh, Hauso Øyvind, Wiseth Rune, Moufack Marcel, Waldum Helge L
Department of Cancer Research and Molecular Medicine, Faculty of Medicine, NTNU , Trondheim , Norway.
Scand Cardiovasc J. 2014 Apr;48(2):106-10. doi: 10.3109/14017431.2014.886335. Epub 2014 Feb 24.
Serotonin (5-HT) most likely plays an important role in the pathogenesis of pulmonary arterial hypertension (PAH). We aimed to test if venous plasma 5-HT is a potential biomarker of PAH. We also measured venous blood β-thromboglobulin (β-TG) in all participants to ensure that any increase in serotonin levels measured is due to platelet release.
Blood samples from patients (n = 9) with pulmonary arterial hypertension (Group 1 of the World Health Organization classification of pulmonary hypertension) as well as healthy volunteers (n = 9) were analyzed. We used enzyme-linked immunosorbent assay (ELISA) to measure venous platelet-poor plasma 5-HT and β-TG in patients with pulmonary arterial hypertension (PAH) and in age-matched normal controls.
Venous platelet-free plasma 5-HT and β-TG were almost similar in patients with PAH and healthy controls with only a slight trend toward increased 5-HT levels in patients with PAH. No correlation was found between venous platelet-poor plasma 5-HT and disease severity. There was no association between venous plasma 5-HT and the mean pulmonary artery pressure.
Our data suggest that 5-HT is not significantly elevated in venous platelet-free plasma in patients with PAH and may accordingly not be a useful biomarker in this condition.
血清素（5-羟色胺，5-HT）很可能在肺动脉高压（PAH）的发病机制中起重要作用。我们旨在测试静脉血浆5-HT是否为PAH的潜在生物标志物。我们还测量了所有参与者静脉血中的β-血小板球蛋白（β-TG），以确保所测得的血清素水平升高是由于血小板释放所致。
分析了肺动脉高压患者（n = 9，世界卫生组织肺动脉高压分类中的第1组）以及健康志愿者（n = 9）的血样。我们使用酶联免疫吸附测定法（ELISA）来测量肺动脉高压（PAH）患者和年龄匹配的正常对照者静脉中血小板缺乏血浆中的5-HT和β-TG。
PAH患者和健康对照者静脉中无血小板血浆中的5-HT和β-TG几乎相似，PAH患者的5-HT水平仅有轻微升高趋势。静脉中血小板缺乏血浆中的5-HT与疾病严重程度之间未发现相关性。静脉血浆5-HT与平均肺动脉压之间无关联。
我们的数据表明，PAH患者静脉中无血小板血浆中的5-HT没有显著升高，因此在这种情况下可能不是一个有用的生物标志物。
